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COMMENTARY
Repurposing Statins for Renal Protection: Is It a Class
Effect?
Stephen J. McWilliam1,∗, Daniel J. Antoine2 and Munir Pirmohamed2
INTRODUCTION
There has been a great deal of excitement regarding the
potential benefits of statins beyond their lipid-lowering
effect, and repurposing them for other indications. In this
commentary, we evaluate the role of statins in protecting
the kidneys, with a focus on three areas: cardiac surgery,
contrast-induced nephropathy, and aminoglycoside-induced
nephrotoxicity.
COMMENTARY
Statins inhibit the activity of 3-hydroxy-3-methylglutaryl CoA
(HMG-CoA) reductase in order to reduce cholesterol syn-
thesis, leading to lower circulating concentrations of total
cholesterol and low-density lipoprotein. In adults, statins
have proven efficacy in reducing morbidity and mortality, and
improving clinical outcomes, in those at risk of vascular dis-
ease. Beyond their lipid-lowering effect, statins have been
reported to have a number of additional beneficial effects,
in particular antiinflammatory and antioxidant effects.1 This
has resulted in their consideration, among other indications,
as potential renal protective agents
POSTOPERATIVE ACUTE KIDNEY INJURY (AKI)
FOLLOWING CARDIAC SURGERY
Cardiac surgery is associated with postoperative AKI in up
to 30% of patients. Etiologically, this is thought to be due to
a combination of ischemia and inflammation. Observational
studies in patients undergoing cardiac surgery who were
already on statins suggested a reduced incidence of AKI,
when comparedwith those not on statins.2 However, a recent
meta-analysis of randomized clinical trials failed to show that
preoperative statins reduced the incidence of postoperative
AKI or requirement for renal replacement therapy.3 Various
statins were used in these trials (including rosuvastatin, ator-
vastatin, and simvastatin), but the meta-analysis grouped
all statins together. This may be a limitation of the meta-
analysis, as there may be differences in the effects of differ-
ent statins (and doses). Furthermore, the analysis was very
dependent on the results of one large negative trial using
rosuvastatin.
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CONTRAST-INDUCED NEPHROPATHY
Systemic injection of contrast media plays a vital role in imag-
ing for both diagnostic and therapeutic interventions. How-
ever, contrast media can cause acute kidney injury, with an
incidence of less than 5% in low-risk patients, increasing
up to 50% in those with diabetes mellitus or chronic kid-
ney disease. The mechanisms are complex and multifacto-
rial, including a decrease in nitric oxide production, increase
in endothelin production, inflammation, and the production of
reactive oxygen species. These factors have been postulated
to reduce renal perfusion and oxygenation, primarily damag-
ing the tubular epithelium and renal vascular endothelium.
Statins have been shown to maintain nitric oxide production,
inhibit the production of reactive oxygen species, and have
other beneficial effects on endothelial function.1 A recent
meta-analysis of 21 randomized controlled trials concluded
that short-term treatment with any statin (the trials used rosu-
vastatin, atorvastatin, or simvastatin) was associated with a
significant reduction in contrast-induced nephropathy (abso-
lute risk reduction 43%).4 A subgroup analysis suggested
that the evidence for a reduction in risk with atorvastatin and
rosuvastatin was good, while it was of low quality with sim-
vastatin. However, without further mechanistic insight and
careful analysis of the dose–response relationship, it is not
yet possible to conclude which statin is the most protective
for this indication.
AMINOGLYCOSIDE-INDUCED NEPHROTOXICITY
Aminoglycoside antibiotics are generally used in clinical
practice to provide Gram-negative cover in the empiri-
cal treatment of suspected sepsis, or to provide targeted
therapy, such as in the treatment of pulmonary exacer-
bations in children with cystic fibrosis (CF) colonized with
Pseudomonas aeruginosa. However, the use of aminoglyco-
sides is limited by their potential to cause nephrotoxicity.
Aminoglycoside-induced nephrotoxicity is characterized
by selective targeting of the proximal tubule epithelial cells
within the renal cortex. Intracellular aminoglycoside results
in apoptosis and necrosis of these cells via a variety of path-
ways (including mitochondrial dysfunction and the release
of reactive oxygen species) (Figure 1).5 Aminoglycosides
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Figure 1 Mechanism of aminoglycoside-induced cytotoxicity in proximal tubule epithelial cells, and proposed mechanism for inhibition
by statins. Adapted from Biochemical Pharmacology, Antoine, D.J. et al. Statins inhibit aminoglycoside accumulation and cytotoxicity to
renal proximal tubule cells, 79, 647–654, C©2010, with permission from Elsevier.
accumulate in proximal tubule cells through endocytosis via
the multi-ligand receptor, megalin. Consistent with this, in
megalin knockout mice, there is no renal accumulation of
aminoglycosides.6
Megalin-mediated endocytosis is dependent on active
guanosine-5’-triphosphate (GTP)-binding proteins, which
require posttranslational modification for trafficking to, and
anchoring in, the cell membrane. Two isoprenoid intermedi-
ates, farnesyl pyrophosphate and geranylgeranyl pyrophos-
phate, play important roles in the prenylation of GTP-
binding proteins. These isoprenoid intermediates are derived
from mevalonate, the downstream product of HMG-CoA
(Figure 1).1
In vitro, statins reduce cholesterol synthesis and increase
unprenylated GTP-binding proteins, leading to inhibition
of megalin-mediated endocytosis.7 In an opossum kidney
cell model, statins (simvastatin, pravastatin, and rosuvas-
tatin) were shown to inhibit cholesterol synthesis in a dose-
dependent manner.8 They also led to a dose-dependent
inhibition of gentamicin accumulation and cytotoxicity (mea-
sured by lactate dehydrogenase leakage), which were related
to the degree of GTP-binding protein unprenylation. Addition
of mevalonate reversed the protective effect of statins, sug-
gesting that inhibition of gentamicin-induced cytotoxicity is
directly related to the inhibition of HMG-CoA and not to any
off-target effect of statins.
Our group has investigated this hypothesis further using
an in vivo guinea pig model (unpublished data). This showed
that gentamicin-induced nephrotoxicity could be inhibited by
rosuvastatin but not by simvastatin, providing evidence of
a differential effect between the two statins, in contrast to
our findings in vitro. This is likely to be due to the different
pharmacokinetics of the two statins in vivo: rosuvastatin has
greater renal elimination through proximal tubule secretion,9
while simvastatin is much more lipophilic and requires hep-
atic metabolism for elimination.
These findings informed the design of a phase IIa ran-
domized controlled clinical trial of rosuvastatin for the pre-
vention of aminoglycoside-induced nephrotoxicity in children
with CF (The PROteKT study; EudraCT 2014-002387-32,
UKCRN ID 16993, ISRCTN26104255). In thismulticenter trial,
50 children with CF receiving clinically indicated treatment
with aminoglycosides were randomized equally to cotreat-
ment with rosuvastatin or to current standard of care. A dose
of 10 mg rosuvastatin was used in the trial based on allo-
metric scaling from the guinea pig experiments. Recruitment
to this trial is now complete, and results will be published in
the near future. This phase IIa study, if positive, will be used
to design a multicenter, phase III trial to evaluate the effect
of rosuvastatin in preventing aminoglycoside-induced kidney
injury.
CONCLUSION
This commentary has showcased the exciting area of drug
repurposing in relation to the use of statins for renal protec-
tion, which is likely to have significant benefits for patients.
To date, the evidence does not support a protective role for
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statins in the prevention of postcardiac surgery AKI. How-
ever, there is good evidence for a protective effect of statins
in contrast-induced nephropathy, although further work is
required to determine the best statin and dose. Finally,
results are awaited from a clinical trial to identify whether
rosuvastatin may protect against aminoglycoside-induced
nephrotoxicity.
Statins all inhibit cholesterol production, but they vary
in their potency with differing dose–response profiles. Fur-
thermore, it is wrong to assume that any drug, including a
statin, will have the same dose–response profile in a repur-
posed indication as it does in its original indication. Similarly,
each statin is likely to differ in its pleiotropic effects. These
effects are dependent on their individual chemical struc-
ture and pharmacology, including disposition. For instance,
a hydrophilic statin, such as rosuvastatin, has greater renal
excretion compared with lipophilic statins such as atorvas-
tatin and simvastatin, suggesting it is likely to have a greater
renal effect. Furthermore, rosuvastatin is secreted in the
proximal tubules,9 which may explain its greater propensity
to cause proteinuria,10 suggesting it is a more potent inhibitor
of megalin-mediated endocytosis, and therefore more likely
to be renoprotective in aminoglycoside exposure. In con-
trast, where the renoprotective mechanism may be related
to antioxidant or antiinflammatory effects, other statins may
be more potent, potentially explaining the utility of atorvas-
tatin for contrast-induced nephropathy.
In conclusion, we would therefore suggest that identi-
fying the correct statin and dose is crucial before tak-
ing a statin forward into large-scale clinical trials for each
new repurposed indication. This will require a combina-
tion of more extensive preclinical work in animal models
and dose-ranging experimental medicine studies in patients.
“Preparation is the key to success” (Alexander Graham
Bell).
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